CD38—Negative Myeloma with Anaplastic Morphology at Presentation: A Case Report
- 49 Downloads
CD38 is a 46-kDa type II trans-membrane glycoprotein involved in receptor-mediated cell adhesion, signal transduction and intracellular calcium metabolism. Normal plasma cells show higher expression of CD38 than the hematopoietic stem cells, T and B lymphocytes. However, malignant plasma cells over-express CD38 at all stages of maturation. In fact, high and consistent expression of CD38 by myeloma cells together with its significance in cell signaling pathways have suggested the role of CD38 as a potential target for the treatment of multiple myeloma (MM). Daratumumab is a humanized CD38 monoclonal antibody that has emerged as a breakthrough targeted therapy in myeloma patients, used both as a monotherapy and in combination with other agents. Recently published studies have documented loss of CD38 in relapsed or refractory myeloma . Here, we report a case of newly diagnosed MM with CD38 negative plasma cells and anaplastic morphology as evaluated by...
Compliance with Ethical Standards
Conflict of interest
The authors state that there is no conflict of interest present.
This case report does not contain any studies with human participants or animals performed by any of the authors. The identity of the patient is not disclosed here in this case.
Human and Animal Rights
The identity of the patient is not disclosed here in this case.